Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047091 | 0.90 | KDR (0.44) | KDRMAPK14 | |
| SCHEMBL1462071 | 0.83 | MAPK14 (0.38) | KDRMAPK14MAPK11 | |
| SCHEMBL4111465 | 0.83 | MAPK14 (0.36) | KDRLMNAMAPK14 | |
| SCHEMBL5738802 | 0.83 | KDR (0.32) | KDRMAPK14FGFR1 | |
| SCHEMBL1459902 | 0.76 | KDR (0.46) | KDRMAPK14 | |
| SCHEMBL14452005 | 0.76 | MAPK14 (0.52) | KDRMAPK14 | |
| SCHEMBL1459917 | 0.75 | MAPK14 (0.39) | KDRMAPK14MAPK11 | |
| SCHEMBL4053344 | 0.75 | MAPK14 (0.42) | KDRMAPK14 | |
| SCHEMBL14469944 | 0.75 | MAPK14 (0.42) | KDRMAPK14 | |
| SCHEMBL14469831 | 0.74 | MAPK14 (0.42) | KDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | KDR 3537/4885LMNA 2288/4885MAPK14 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.